Key result
Treatment of human platelets with factor Xa (10 nM) inhibited thrombin-induced thromboxane A2 synthesis by 70%, demonstrating a countervailing effect to its stimulation of thrombin formation.
Why the study?
Does factor Xa inhibit thromboxane A2 synthesis in human platelets?
Does factor Xa inhibit thromboxane A2 synthesis in human platelets?
Factor Xa binding to platelets through factor Va not only stimulates thrombin formation but also inhibits TXA2 formation, revealing a countervailing regulatory mechanism in platelet activation.
May amplify platelet responses in vivo; leaves open targeted interventions pending clinical studies.
Factor Xa binds to platelets provided that factor Va is present on the platelet surface, an interaction that results in a striking acceleration of the conversion of prothrombin to thrombin. Thrombin then initiates fibrin formation, induces platelet aggregation, and stimulates the intraplatelet synthesis of thromboxane A2 (TXA2). Addition of thrombin (2.4-14.4 nM) to platelet-rich plasma increased the basal level of TXA2, measured as thromboxane B2, from less than 0.5 pmol per 10(8) platelets to (mean +/- SEM) 100 +/- 22 and 250 +/- 10 pmol per 10(8) platelets, respectively. Treatment of platelet-rich plasma with increasing concentrations of factor Xa (1-12 nM) prior to the addition of thrombin progressively inhibited the production of TXA2. Thrombin (9.6 nM), which produced 93% of the maximal formation of TXA2, was inhibited 70% by factor Xa (10 nM). To identify which of these steps in thromboxane synthesis was inhibited by factor Xa, platelets labeled with [14C]arachidonic acid were exposed to thrombin and products of prostaglandin synthesis were separated by thin-layer chromatography. In contrast to the inhibition of TXA2 synthesis, prostaglandin E2 and prostaglandin F2 alpha synthesis were not inhibited suggesting that neither phospholipase(s) nor cycloxygenase was involved. The inhibition of TXA2 formation by factor Xa could be reversed by increasing the molar ratio of thrombin to factor Xa to 5.5. Incubation of platelets with an IgG fraction of a human monoclonal antifactor V antibody, previously shown to inhibit factor Xa binding, was found to block factor Xa inhibition of TXA2 synthesis. The inhibition of TXA2 synthesis requires the presence of the active site serine of factor Xa and is not specific for TXA2 formation induced by thrombin because it is also demonstrable when the agonist is ADP. Further, factor Xa does not require additional plasma components for its action because its inhibitory effects are detected in gel-filtered platelets. The effect of factor Xa was evident at physiological (1.3 mM) calcium concentrations. These results indicate that factor Xa binding to platelets through factor Va not only stimulates thrombin formation but also has a countervailing effect by inhibiting TXA2 formation.
No takes yet. Share an insight, caveat, or question.
Sinha et al. (1983) studied this question. Factor Xa vs. Thrombin alone was evaluated on Thromboxane A2 (TXA2) synthesis. Treatment of human platelets with factor Xa (10 nM) inhibited thrombin-induced thromboxane A2 synthesis by 70%, demonstrating a countervailing effect to its stimulation of thrombin formation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: